A Brave New Paradigm for M&A - Serial Acquisition Options

Authored by Han Smit, Professor of Corporate Finance, Erasmus University, Netherlands
Authored by Thras Moraitis, FORMER Executive General Manager Group Strategy and Corporate Affairs, Xstrata plc, London, United Kingdom

A serial M&A strategy is a powerful strategic option for businesses wishing to grow in a specific market or for a private equity firm pursuing a buy-and-build strategy. Thras Moraitis, Executive General Manager Group Strategy and Corporate Affairs at Xstrata plc, and Han Smit, Professor of Corporate Finance at Erasmus University, reveal how some fresh thinking is needed to deliver a successful acquisition strategy.

Share this with your Community




Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

BLOG | A Long-term View of the Business Landscape

Last week, we hosted a Leadership in the Boardroom Dinner: A Long-term View of the Business Landscape, bringing together Board members and senior executives to discuss the economic, technological and geopolitical for...


Click here to download this insight

Technology Transformation is Not an IT Issue - It's a Leadership One

Successful transformation is not won by process alone. This article by Criticaleye Partner Hitachi Solutions explores the culture of partnership and the executive behaviours that turn plans into results. The piece ...


Criticaleye Asia Podcast - HR as a Strategic Partner in Complexity

In this episode, Yu-Wen Hsiao, Marketing and Communications Manager, APAC at Criticaleye, speaks with Kathleen Kee, VP, HR – EMEA & Asia at Santen, about what it takes to lead people and performance in an i...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 175




NATS Worldpay E.ON UK Legal & General Drax Group plc NatWest Group Rolls-Royce Lightsource bp Aldermore Group British Land Hitachi Solutions London Stock Exchange Group Canaccord Genuity Group Inc AlixPartners GlaxoSmithKline plc LACE Partners Mayborn Group